Iridex Corporation has announced the benefits of MicroPulse photocoagulation technology over the standard-of-care treatment for diabetic macular oedema retinal damage caused by diabetes.
MicroPulse technology is a tissue-sparing laser emission that “chops” laser trains into microsecond pulses, which enhances the potential for ocular treatment options with greater efficiency and with less collateral effects.
The randomised, controlled and double-masked clinical study involved 123 patients and showed that the device was effective in improving visual acuity with the added advantages of causing no localised laser scars.
Iridex president and CEO Theodore Boutacoff said, “This is the first study to demonstrate a significant improvement in best corrected visual acuity using subthreshold diode laser MicroPulse treatment compared to the standard laser photocoagulation treatment of diabetic macular oedema.”
Related
Related Companies
